KYMR's Business Model
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
| Sector & Industry | Healthcare / Biotechnology |
| Website | https://www.kymeratx.com |
| CEO (Chief Executive Officer) | Nello Mainolfi |
| Number of Employees | |
| IPO date | August 21, 2020 |
KYMR Latest News
|
|
|
|
|
|
|
|
|
|
| Contact | |
|---|---|
| Country | US |
| Address | 200 Arsenal Yards Boulevard |
| City | Watertown |
| State | MA |
| Phone | 857 285 5300 |
| Zip Code | 02472 |
| Other Identifiers | |
| CIK | 0001815442 |
| ISIN | US5015751044 |
| CUSIP | 501575104 |
| Open | 76.515 |
| Previous Close | 75.62 |
| Volume | 632.4 Thou. |
| Average Volume | 971.6 Thou. |
| Day’s Range | 75.16 – 78.91 |
| 52 Week Range | 19.445-103 |
| MA (50) | 75.0378 |
| MA (200) | 53.03838 |
| Market Cap | 6.1 Bil. |
| Shares Out. | 78.95 Mil. |
| Earnings Date | Feb 19, 2026 |
| Beta | |
| Last Dividend | |
| EPS | |
| PE | |
